Domokos Gero1, Csaba Szabo1. 1. Department of Anesthesiology, University of Texas Medical Branch, Galveston, TX, USA.
Abstract
BACKGROUND AND PURPOSE: Ischaemic heart disease can lead to serious, life-threatening complications. Traditional therapies for ischaemia aim to increase oxygen delivery and reduce the myocardial ATP consumption by increasing the coronary perfusion and by suppressing cardiac contractility, heart rate or blood pressure. An adjunctive treatment option for ischaemia is to improve or optimize myocardial metabolism. EXPERIMENTAL APPROACH: Metabolic suppression in the ischaemic heart is characterized by reduced levels of high-energy molecules: ATP and NAD(+) . Because NAD(+) is required for most metabolic processes that generate ATP, we hypothesized that restoration of NAD(+) would be a prerequisite for ATP regeneration and examined the role of the major NAD(+) anabolic and catabolic pathways in the bioenergetic restoration process following oxygen-glucose deprivation injury in a cardiomyocyte cell line (H9c2 cells). KEY RESULTS: Salvage of NAD(+) via nicotinamide phosphoribosyl transferase was essential for bioenergetic recovery in cardiomyocytes. Blockade of nicotinamide phosphoribosyl transferase prevented the restoration of the cellular ATP pool following oxygen-glucose deprivation injury by inhibiting both the aerobic and anaerobic metabolism in the cardiomyocytes. NAD(+) consumption by PARP-1 also undermined the recovery processes, and PARP inhibition significantly improved the metabolism and increased cellular ATP levels in cardiomyocytes. CONCLUSIONS AND IMPLICATIONS: We conclude that the NAD(+) salvage pathway is essential for bioenergetic recovery in post-hypoxic cardiomyocytes and PARP inhibition may represent a potential future therapeutic intervention in ischaemic heart disease.
BACKGROUND AND PURPOSE:Ischaemic heart disease can lead to serious, life-threatening complications. Traditional therapies for ischaemia aim to increase oxygen delivery and reduce the myocardial ATP consumption by increasing the coronary perfusion and by suppressing cardiac contractility, heart rate or blood pressure. An adjunctive treatment option for ischaemia is to improve or optimize myocardial metabolism. EXPERIMENTAL APPROACH: Metabolic suppression in the ischaemic heart is characterized by reduced levels of high-energy molecules: ATP and NAD(+) . Because NAD(+) is required for most metabolic processes that generate ATP, we hypothesized that restoration of NAD(+) would be a prerequisite for ATP regeneration and examined the role of the major NAD(+) anabolic and catabolic pathways in the bioenergetic restoration process following oxygen-glucose deprivation injury in a cardiomyocyte cell line (H9c2 cells). KEY RESULTS: Salvage of NAD(+) via nicotinamide phosphoribosyl transferase was essential for bioenergetic recovery in cardiomyocytes. Blockade of nicotinamide phosphoribosyl transferase prevented the restoration of the cellular ATP pool following oxygen-glucose deprivation injury by inhibiting both the aerobic and anaerobic metabolism in the cardiomyocytes. NAD(+) consumption by PARP-1 also undermined the recovery processes, and PARP inhibition significantly improved the metabolism and increased cellular ATP levels in cardiomyocytes. CONCLUSIONS AND IMPLICATIONS: We conclude that the NAD(+) salvage pathway is essential for bioenergetic recovery in post-hypoxic cardiomyocytes and PARP inhibition may represent a potential future therapeutic intervention in ischaemic heart disease.
Authors: Jan P Roesner; Jan Mersmann; Stefan Bergt; Karl Bohnenberg; Carmen Barthuber; Csaba Szabo; Gabriele E F Nöldge-Schomburg; Kai Zacharowski Journal: Shock Date: 2010-05 Impact factor: 3.454
Authors: Fabrizio Montecucco; Inga Bauer; Vincent Braunersreuther; Santina Bruzzone; Alexander Akhmedov; Thomas F Lüscher; Timo Speer; Alessandro Poggi; Elena Mannino; Graziano Pelli; Katia Galan; Maria Bertolotto; Sébastien Lenglet; Anna Garuti; Christophe Montessuit; René Lerch; Corinne Pellieux; Nicolas Vuilleumier; Franco Dallegri; Jacqueline Mage; Carlos Sebastian; Raul Mostoslavsky; Angèle Gayet-Ageron; Franco Patrone; François Mach; Alessio Nencioni Journal: Antioxid Redox Signal Date: 2012-05-14 Impact factor: 8.401
Authors: Andrea Molnár; Attila Tóth; Zsolt Bagi; Zoltán Papp; István Edes; Miklós Vaszily; Zoltán Galajda; Julius Gy Papp; András Varró; Viktória Szüts; Zsombor Lacza; Domokos Gerö; Csaba Szabó Journal: Mol Med Date: 2006 Jul-Aug Impact factor: 6.354
Authors: David A Morrow; Chaim M Brickman; Sabina A Murphy; Kenneth Baran; Ricardo Krakover; Harold Dauerman; Sujatha Kumar; Natanya Slomowitz; Laura Grip; Carolyn H McCabe; Andrew L Salzman Journal: J Thromb Thrombolysis Date: 2008-06-06 Impact factor: 2.300
Authors: Carrie A Sims; Yuxia Guan; Sarmistha Mukherjee; Khushboo Singh; Paul Botolin; Antonio Davila; Joseph A Baur Journal: JCI Insight Date: 2018-09-06
Authors: Domokos Gerő; Roberta Torregrossa; Alexis Perry; Alicia Waters; Sophie Le-Trionnaire; Jacqueline L Whatmore; Mark Wood; Matthew Whiteman Journal: Pharmacol Res Date: 2016-08-23 Impact factor: 7.658